🇺🇸 FDA
Patent

US 10683347

Treatment of cancer using anti-TGF-β and anti-PD-1 antibodies

granted A61KA61K2039/507A61K2039/57

Quick answer

US patent 10683347 (Treatment of cancer using anti-TGF-β and anti-PD-1 antibodies) held by The Regents of the University of California expires Mon Jun 11 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Jun 16 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 11 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K2039/507, A61K2039/57, A61P, A61P35/00